...
首页> 外文期刊>ACS medicinal chemistry letters >Design and Evaluation of Heterobivalent PAR1–PAR2 Ligands as Antagonists of Calcium Mobilization
【24h】

Design and Evaluation of Heterobivalent PAR1–PAR2 Ligands as Antagonists of Calcium Mobilization

机译:异常PAR1-PAR2配体的设计与评估钙动员的拮抗剂

获取原文
获取原文并翻译 | 示例

摘要

A novel class of bivalent ligands targeting putative protease-activated receptor (PAR) heteromers has been prepared based upon reported antagonists for the subtypes PAR1 and PAR2. Modified versions of the PAR1 antagonist RWJ-58259 containing alkyne adapters were connected via cycloaddition reactions to azide-capped polyethylene glycol (PEG) spacers attached to imidazopyridazine-based PAR2 antagonists. Initial studies of the PAR1–PAR2 antagonists indicated that they inhibited G alpha q-mediated calcium mobilization in endothelial and cancer cells driven by both PAR1 and PAR2 agonists. Compounds of this novel class hold promise for the prevention of restenosis, cancer cell metastasis, and other proliferative disorders.
机译:基于报道的亚型PAR1和PAR2,已经制备了一种新型靶向蛋白酶活化受体(Par)异构体的二偶联配体(Par)异构体。 将含有炔酮适配器的PAR1拮抗剂RWJ-58259的改性版本通过环加成反应与附着在基于咪唑吡啶基的PAR2拮抗剂的叠氮盖聚乙二醇(PEG)间隔物连接。 PAR1-PAR2拮抗剂的初步研究表明,它们抑制了PAR1和PAR2激动剂驱动的内皮和癌细胞中的GαQ介导的钙动员。 这种新型阶级的化合物持有预防再狭窄,癌细胞转移和其他增殖性疾病的承诺。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号